Improved Breast MRI With SWIFT

University of Minnesota31 enrolled

Overview

Today's medical imaging methods have insufficient specificity for reliable differentiation between benign and malignant breast lesions in patients. Pathologic evaluation is currently the only way to obtain a definitive diagnosis. This research will use a novel method of magnetic resonance imaging (MRI), Sweep Imaging with Fourier Transform (SWIFT), at a very high magnetic field (4 Tesla) to distinguish malignant from benign breast lesions. This research will reveal whether the SWIFT sequence bears new capabilities in medical imaging for breast cancer diagnosis.

Patients will be asked to come to the Center for Magnetic Resonance Research (CMRR) at the University of Minnesota. Researchers will interview the patient and describe procedures and risks. An intravenous (IV) line will be placed in an upper extremity for infusing magnetic resonance imaging (MRI) contrast dye. Baseline MRI scans will be done. These MRI measurements will be compared with clinical, radiological and pathological findings (the gold standard). Follow-up contact will occur within one year after the MRI to determine whether a pathology report is available.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

Magnetic resonance imagingDEVICE

Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows: * an IV line is placed by nurse, * patient is placed in the 4 T MRI scanner at CMRR, * initial scout images and manual linear shims are adjusted, * Pre-contrast SWIFT T1 weighted images and T1 map are obtained, * continuous SWIFT acquisition begins immediately before contrast injection, * contrast injection, * continuous SWIFT acquisition continues for 12 min after contrast, * late enhancement images may also be obtained. 10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women with a clinically or mammographically identified suspicious breast mass that is likely to be biopsied or surgically removed. Exclusion Criteria: * Pregnancy * Ferromagnetic implants * History of shotgun wounds and shrapnel * Obesity (\>250 pounds) * Cardiac pacemaker * Incompatible implanted medical device * Severe claustrophobia * Major surgeries with potential of ferromagnetic implants * Severe asthma and allergies * i-STAT system, a handheld blood analyzer (I-STAT) creatinine test, estimated glomerular filtration rate (GFR) \<30 * Metallic object (greater than 2 cm in length) in the breast * Metallic ink tatoo within 20 cm of the breast (approximately 8 inches)

Locations (1)

Center for Magnetic Resonance Research

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Lesions

Number of lesions detected

Time frame: at time of read by two radiologiests, compared to biopsy within 7 days.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.